Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury (SEVOKID)

University Hospital, Clermont-Ferrand

Status and phase: Unknown; Phase 2

Conditions: Acute Kidney Injury

Treatments: Drug: Sedation with sevoflurane during 48-hr in ICU

Study type: Interventional

Funder types: Other

Identifiers

NCT02042599

2012-005746-37

CHU-0175

Details and patient eligibility

About

Describing a pharmacokinetic model of 48-h sevoflurane sedation in ICU patients with acute kidney failure

Full description

Prospective clinical monocentric study in ICU with sedated ventilated patients (presenting acute kidney failure) with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)

Enrollment: 12 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line AKIN score = 3

Exclusion criteria

• BMI <30 Sevoflurane anaphylaxia

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

sevoflurane

Experimental group

Description:

Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury

Treatment:

Drug: Sedation with sevoflurane during 48-hr in ICU